Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.53 |
| ▸ | RAB9A | P51151 | 7/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.47 |
| ▸ | RELA | Q04206 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6647582 | 0.78 | RAB9A (0.67) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL12548965 | 0.76 | NPC1 (0.63) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL3401020 | 0.76 | MAPK1 (0.64) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL15699765 | 0.75 | MAPT (0.52) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL1347633 | 0.75 | HDAC3 (0.50) | RAB9ACNR1CNR2 | |
| SCHEMBL211598 | 0.75 | ALDH1A1 (0.69) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL19043117 | 0.73 | DRD2 (0.61) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL21207308 | 0.73 | ALDH1A1 (0.52) | NPC1RAB9ASMN1; SMN2ALDH1A1ALOX15 | |
| SCHEMBL23617613 | 0.73 | NPC1 (0.63) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL10009486 | 0.72 | MAPT (0.63) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063240-B2 | Prostaglandin E1 and E2 analogs for the treatment of various medical conditions | CAYMAN CHEMICAL COMPANY, INCORPORATED (US) | 2011-11-22 | — | — | US | disclosed |
| US-20090221654-A1 | PROSTAGLANDIN E1 AND E2 ANALOGS FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS | CAYMAN CHEMICAL COMPANY (US) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221654-A1 | PROSTAGLANDIN E1 AND E2 ANALOGS FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS | PTGER1, PTGER4, PTGER2 | NPC1 3569/4885RAB9A 869/4885SMN1; SMN2 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.